Following the acquisition from Viatris, Biocon Biologics and its partners state that they will commercialise biosimilar products in 31 European countries.
List view / Grid view
IMbrave050 is the first Phase III study to show a cancer immunotherapy combo reduced risk of disease recurrence for early-stage hepatocellular carcinoma.
Highlights of the February 2022 meeting of EMA’s human medicines committee (CHMP) include the recommendation of 13 medicines for approval, along with updates to other drugs and COVID-19 vaccines.
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
A Phase I/IIa study has shown that arfolitixorin along with either irinotecan or oxaliplatin could shrink the size of tumours in colorectal cancer patients...
A new study reveals the efficacy and safety of using intravenous bevacizumab to treat patients with severe hereditary haemorrhagic telangiectasia (HHT). Successful results suggest it should be used as a first-line therapy.
The European Commission has granted marketing authorisation for Mvasi for the treatment of certain types of cancer...